A randomized, double blind, placebo controlled, multi-centric, trial to determine the therapeutic efficacy of Ayush medicine NOQ19 in treatment of symptomatic COVID-19 patients along with standard allopathic treatment

The current pandemic of Covid-19 has shaken the entire world. In spite of various scientific researches and technological advancements exact treatement to cure the disease is yet to be discovered. Ayurvedic medicine NOQ 19 is a polyherbal formulation that has immunomodulating and immune enhancing properties. This drug is licensed by Drug licensing authority, Department of AYUSH, Government of Karnataka. The present randomized, double blind, placebo controlled, multi-centric trial is planned to determine the therapeutic efficacy of Ayurvedic medicine NOQ19 in treatment of symptomatic COVID-19 patients along with standard allopathic treatment. Three medical institutes providing Covid 19 care will be involved in conducting this trial. From each center 50 covid positive patients admitted in the hospital in the age group 18-75 years will be recruited and randomized into treatment and control arm.  Following randomization 25 of them will be given Ayurvedic medicine NOQ 19 along with standard treatment and other 25 will receive placebo plus standard treatment. The follow up period will be 7 days. Outcome measures that will be assessed are time to become SARS CoV2 RT PCR negative, reduction in symptoms and duration of hospital stay. Apart from this the blood samples will be collected on the day of entry and exit to measure CBC, RBS, KFT, LFT,  CRP.